David Sumerauer
Overview
Explore the profile of David Sumerauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Misove A, Vicha A, Broz P, Vanova K, Sumerauer D, Stolova L, et al.
Acta Neuropathol Commun
. 2022 Sep;
10(1):143.
PMID: 36163281
Gliomas are the most common central nervous tumors in children and adolescents. However, spinal cord low-grade gliomas (sLGGs) are rare, with scarce information on tumor genomics and epigenomics. To define...
12.
Federico A, Thomas C, Miskiewicz K, Woltering N, Zin F, Nemes K, et al.
Acta Neuropathol
. 2022 May;
143(6):697-711.
PMID: 35501487
Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive central nervous system tumor characterized by loss of SMARCB1/INI1 protein expression and comprises three distinct molecular groups, ATRT-TYR, ATRT-MYC and ATRT-SHH. ATRT-SHH represents...
13.
Benes 3rd V, Zapotocky M, Liby P, Taborsky J, Blazkova Jr J, Blazkova Sr J, et al.
Acta Neurochir (Wien)
. 2022 Jan;
164(6):1459-1472.
PMID: 35043265
Background: Childhood thalamopeduncular gliomas arise at the interface of the thalamus and cerebral peduncle. The optimal treatment is total resection but not at the cost of neurological function. We present...
14.
Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone S, et al.
Nat Med
. 2022 Jan;
28(1):125-135.
PMID: 34992263
Cancers arising from germline DNA mismatch repair deficiency or polymerase proofreading deficiency (MMRD and PPD) in children harbour the highest mutational and microsatellite insertion-deletion (MS-indel) burden in humans. MMRD and...
15.
Vicha A, Stolova L, Jencova P, Zapotocky M, Sumerauer D, Misove A, et al.
Cesk Patol
. 2021 Sep;
57(3):154-160.
PMID: 34551564
Examination of changes in the methylation profile of DNA in cancer is currently used to determine the diagnosis or prognostic and predictive biomarkers. It complements histological or molecular biological examinations....
16.
Deng M, Sturm D, Pfaff E, Sill M, Stichel D, Balasubramanian G, et al.
Nat Commun
. 2021 Sep;
12(1):5530.
PMID: 34545083
Long-term complications such as radiation-induced second malignancies occur in a subset of patients following radiation-therapy, particularly relevant in pediatric patients due to the long follow-up period in case of survival....
17.
AlHalabi K, Stichel D, Sievers P, Peterziel H, Sommerkamp A, Sturm D, et al.
Acta Neuropathol
. 2021 Aug;
142(5):841-857.
PMID: 34417833
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic...
18.
Steinbugl M, Nemes K, Johann P, Kroncke T, Tuchert S, da Costa M, et al.
Pediatr Blood Cancer
. 2021 Aug;
68(12):e29267.
PMID: 34347371
Background: Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent,...
19.
von Hoff K, Haberler C, Schmitt-Hoffner F, Schepke E, de Rojas T, Jacobs S, et al.
Neuro Oncol
. 2021 Jun;
23(9):1597-1611.
PMID: 34077956
Background: Only few data are available on treatment-associated behavior of distinct rare CNS embryonal tumor entities previously treated as "CNS-primitive neuroectodermal tumors" (CNS-PNET). Respective data on specific entities, including CNS...
20.
Durno C, Ercan A, Bianchi V, Edwards M, Aronson M, Galati M, et al.
J Clin Oncol
. 2021 May;
39(25):2779-2790.
PMID: 33945292
Purpose: Constitutional mismatch repair deficiency syndrome (CMMRD) is a lethal cancer predisposition syndrome characterized by early-onset synchronous and metachronous multiorgan tumors. We designed a surveillance protocol for early tumor detection...